# Hiroaki Akamatsu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hiroaki-akamatsu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,690 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 38 |
| i10-index | 106 |
| Last Known Institution | Wakayama Medical University |
| OpenAlex ID | https://openalex.org/A5084260472 |
| ORCID iD | 0000-0001-5856-5512 |
| Works | 348 |

## Researcher papers

- [Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/)
- [Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-durvalumab-for-resectable-non-small-cell-lung-cancer/)
- [Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer](https://scholariq.org/papers/tarlatamab-for-patients-with-previously-treated-small-cell-lung-cancer/)
- [Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab](https://scholariq.org/papers/correlation-between-immune-related-adverse-events-and-efficacy-in-non-small-cell/)
- [Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis](https://scholariq.org/papers/osimertinib-versus-platinum-pemetrexed-for-patients-with-egfr-t790m-advanced/)
- [Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer](https://scholariq.org/papers/nivolumab-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-treatment/)
- [Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor](https://scholariq.org/papers/efficacy-of-osimertinib-plus-bevacizumab-vs-osimertinib-in-patients-with-i-egfr/)
- [Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer](https://scholariq.org/papers/prognostic-impact-of-cancer-cachexia-in-patients-with-advanced-non-small-cell/)
- [Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System](https://scholariq.org/papers/size-based-isolation-of-circulating-tumor-cells-in-lung-cancer-patients-using-a/)
- [Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors](https://scholariq.org/papers/predictive-and-sensitive-biomarkers-for-thyroid-dysfunctions-during-treatment/)
- [Histologic transformation of epidermal growth factor receptor–mutated lung cancer](https://scholariq.org/papers/histologic-transformation-of-epidermal-growth-factor-receptor-mutated-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Wakayama Medical University](https://scholariq.org/institutions/wakayama-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.